Theravance Biopharma, Inc.
NASDAQ:TBPHBiotechnology
Healthcare
$17.03 -0.42%
-$0.07 today
- Market cap
- $882.64M
- Beta
- 0.18
- P/E (TTM)
- 7.4
- EPS (TTM)
- $2.23
52W Low $10.44High $21.03
Volume 10.02M
Average 0.43M
Balance Sheet
Inspect the capital base behind the business.
Assets
$485.57M
FY 2025 · Annual
+37.1% YoYLiabilities
$188.85M
FY 2025 · Annual
+5.7% YoYEquity
$296.72M
FY 2025 · Annual
+69.0% YoYBalance Sheet
USD
Metric | FY 2021 Dec 2021 | FY 2022 Dec 2022 | FY 2023 Dec 2023 | FY 2024 Dec 2024 | FY 2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 89.96M | 298.17M | 39.55M | 37.8M | 167.81M |
| Short-term Investments | 83.51M | 29.31M | 62.88M | 50.55M | 147.55M |
| Net Receivables | 57.6M | 16.79M | 17.47M | 68.44M | 95.54M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 8.56M | 7.68M | 11.6M | 4.2M | 7.56M |
| Total Current Assets | 249.87M | 353.46M | 133.54M | 161.07M | 418.46M |
| Property, Plant & Equipment (Net) | 53.35M | 52M | 45.36M | 35.77M | 30.27M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 68.37M | 0 | 0 | 0 | 14.35M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 3.23M | 201.94M | 203.1M | 157.32M | 22.5M |
| Total Non-current Assets | 124.95M | 253.94M | 248.46M | 193.09M | 67.11M |
| Total Assets | 374.82M | 607.4M | 382M | 354.16M | 485.57M |
| Account Payables | 3.1M | 1.55M | 1.52M | 2.24M | 2.57M |
| Short-term Debt | 17.44M | 0 | 0 | 0 | 10.95M |
| Tax Payables | 0 | 0 | 0 | 5.85M | 0 |
| Deferred Revenue | 98K | 24K | 0 | 0 | 0 |
| Other Current Liabilities | 25.15M | (24K) | 12.88M | 0 | 6.91M |
| Total Current Liabilities | 58.59M | 28.72M | 24.77M | 32.09M | 38.3M |
| Long-term Debt | 599.39M | 0 | 0 | 0 | 32.8M |
| Deferred Tax Liabilities | 240K | 0 | 0 | 0 | 85.68M |
| Deferred Revenue (Non-current) | 310K | 192K | 0 | 0 | 0 |
| Other Non-current Liabilities | 2.18M | 91.29M | 99M | 107.42M | 313K |
| Total Non-current Liabilities | 654.81M | 136.89M | 144.24M | 146.53M | 150.55M |
| Total Liabilities | 713.39M | 165.6M | 169M | 178.62M | 188.85M |
| Common Stock | 1K | 1K | 0 | 0 | 1K |
| Retained Earnings | (1.73B) | (853.91M) | (909.1M) | (965.52M) | (859.63M) |
| Accumulated OCI | (0) | (15K) | (65K) | 7K | 61K |
| Other Stockholders Equity | 0 | 0 | (0) | (0) | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | (338.57M) | 441.8M | 213M | 175.55M | 296.72M |
| Total Debt | 669.52M | 52.16M | 49.16M | 49.82M | 75.5M |
| Net Debt | 579.56M | (246.01M) | 9.61M | 12.02M | (92.31M) |
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $288.1M |
| Short-term Investments | $106.6M |
| Receivables | $15.6M |
| Other Current | $7.4M |
| Total Current Assets | $417.6M |
| PP&E (Net) | $28.5M |
| Long-term Investments | $836.0K |
| Other Non-current | $25.3M |
| Total Non-current Assets | $54.7M |
| Total Assets | $472.3M |
Analysis
Selected assets total $472.3M for Latest. The largest visible component is Cash & Equivalents at $288.1M, about 61.0% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13D/A | SC 13D/A filing | Sep 25, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 24, 2026 | |
| S-8 POS | S-8 POS filing | Sep 24, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 24, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 24, 2026 |
How much cash does TBPH have?
Theravance Biopharma, Inc. (TBPH) reported $167.81M in cash and equivalents in fiscal 2025.
How much debt does TBPH carry?
Theravance Biopharma, Inc. (TBPH) reported $75.50M of total debt, with net debt of -$92.31M.
Continue the stock analysis
Jump to another research area for this company.